<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823849</url>
  </required_header>
  <id_info>
    <org_study_id>246-08-802-01</org_study_id>
    <nct_id>NCT00823849</nct_id>
  </id_info>
  <brief_title>Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker</brief_title>
  <official_title>A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Beijing Research Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Beijing Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate the efficacy of Cilostazol and Probucol alone and in combination on
           atherosclerosis related biomarker

        2. To evaluate the safety of Cilostazol and Probucol alone and in combination on
           atherosclerosis related biomarker
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy evaluation:

      Primary efficacy index:

      After 12 weeks of treatment, the change of arteriosclerosis related biomarker in 4 modality
      groups, comparing with the base line information

      Secondary efficacy index:

      After 8 weeks of treatment, the change of arteriosclerosis related biomarker in 4 modality
      groups, comparing with the base line information

      Safety evaluation:

        1. Adverse Event

        2. Vital Sign and Physical Examination

        3. 12-lead ECG

        4. Laboratory Tests (including blood routine examination, routine urine analysis, blood
           biochemistry examination, glycosylated hemoglobin)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Evaluation: Comparing with the basic line information, the change value of arteriosclerosis related biomarker in 4 groups after 12 weeks of treatment.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Arteriosclerosis Obliterans</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>pletaal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probucol</intervention_name>
    <description>250 mg Bid, PO after breakfast and dinner.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Changtai</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol+Probucol</intervention_name>
    <arm_group_label>3</arm_group_label>
    <other_name>Pletaal and Changtai</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>Routine treatment</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Routine treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  40~75-year-old male or female

          -  Clarified diagnosis of type 2 diabetes mellitus

          -  Arteriosclerosis obliterans (ASO) is diagnosed (ASO diagnoses should meet at least one
             of the conditions as below:

               -  ABI&lt;1.0;

               -  The pulse of popliteal artery or dorsalis pedis artery is weeken significantly or
                  is different between left and right sides

               -  Intermittent claudication, diagnosed as ASO by doctor

               -  Ultrasonogram showed that there was atherosclerotic plaque in lower limb within 1
                  year

          -  Informed Consent Form Signature

        Exclusion Criteria:

          -  Has an allergic history to study drugs

          -  Use one of the following drugs: other antiplatelet or anticoagulation agents except
             Aspirin, other hypolipidemic agents except Statins

          -  Type 1 diabetes mellitus, specific diabetes mellitus, or gestational diabetes mellitus

          -  Has severe ASO above Fontaine IIb,

          -  Hemorrhagic tendency or hemorrhagic disease (such as gastrointestinal tract
             hemorrhage, etc.)

          -  Had a myocardial infarction, angina pectoris, or cerebral infarction within the last 3
             months

          -  Congestive heart failure

          -  Is pregnant, or potentially pregnant, or breastfeeding

          -  Severe hepatic insufficient or severe renal insufficiency (AST or ALT is 2.5 times
             higher than the upper limit of the normal value range, or serum creatinine is 1.2
             times higher than the upper limit of the normal value range)

          -  Persistent or hardly controlled hypertension (such as malignant hypertension, BP&gt;
             160/100 mmHg)

          -  Severe ventricular arrhythmia (such as multiple and multifocal premature ventricular
             contractions)

          -  Has a medical history that includes a cardiac syncope or a primary syncope

          -  Has conditions that may prolong QT interval (such as congenital long QT syndrome,
             taking drugs which prolong QT interval, hypokalemia or hypomagnesemia, etc.)

          -  Has severe complications (such as diabetes mellitus ketoacidosis, nonketotic
             hyperosmolar diabetic coma, malignant tumor, severe anaemia, severe hematologic
             diseases, etc.)

          -  Other conditions that would exclude the subject from this study by doctor's judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaohui Guo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>No 1 Hospital of Peking University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2009</study_first_submitted>
  <study_first_submitted_qc>January 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <last_update_submitted>April 21, 2010</last_update_submitted>
  <last_update_submitted_qc>April 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Quanjie Wei</name_title>
    <organization>Otsuka Beijing Research Institute</organization>
  </responsible_party>
  <keyword>type 2 diabetes mellitus, with Arteriosclerosis obliterans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Arteriosclerosis Obliterans</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Probucol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

